These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10971203)

  • 1. The CYP2C19 enzyme polymorphism.
    Wedlund PJ
    Pharmacology; 2000 Sep; 61(3):174-83. PubMed ID: 10971203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotyping of drug metabolism in infants and children: potentials and problems.
    Rane A
    Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients.
    Mamiya K; Ieiri I; Miyahara S; Imai J; Furuumi H; Fukumaki Y; Ninomiya H; Tashiro N; Yamada H; Higuchi S
    Pharmacogenetics; 1998 Feb; 8(1):87-90. PubMed ID: 9511186
    [No Abstract]   [Full Text] [Related]  

  • 4. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4.
    Garcia-Barceló M; Chow LY; Kum Chiu HF; Wing YK; Shing Lee DT; Lam KL; Waye MM
    Clin Chem; 1999 Dec; 45(12):2273-4. PubMed ID: 10585366
    [No Abstract]   [Full Text] [Related]  

  • 5. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
    Yokoi T; Kamataki T
    Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of cytochromes P450.
    Hasler JA
    Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
    [No Abstract]   [Full Text] [Related]  

  • 8. Individual and ethnic differences in CYP2C19 activity in Chinese populations.
    Shu Y; Zhou HH
    Acta Pharmacol Sin; 2000 Mar; 21(3):193-9. PubMed ID: 11324414
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic polymorphism of CYP2A6 in the German population.
    Bourian M; Gullstén H; Legrum W
    Toxicology; 2000 Apr; 144(1-3):129-37. PubMed ID: 10781880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population.
    Itoh K; Inoue K; Nakao H; Yanagiwara S; Tada H; Suzuki T
    Anal Biochem; 2000 Aug; 284(1):160-2. PubMed ID: 10933870
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
    Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic polymorphisms of drug metabolizing enzymes].
    Fujieda M; Yamazaki H; Kamataki T
    Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans.
    Edeki TI; Goldstein JA; de Morais SM; Hajiloo L; Butler M; Chapdelaine P; Wilkinson GR
    Pharmacogenetics; 1996 Aug; 6(4):357-60. PubMed ID: 8873222
    [No Abstract]   [Full Text] [Related]  

  • 16. Populations and genetic polymorphisms.
    Weber WW
    Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CYP2A6 and CYP2C19 mutant alleles.
    Lam K; Chow L; Leung T; Wing YK; Chiu HF; Garcia-Barceló M
    Clin Pharmacol Ther; 1999 Dec; 66(6):647. PubMed ID: 10613622
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].
    Alonso-Navarro H; Jiménez-Jiménez FJ; García-Agúndez JA
    Med Clin (Barc); 2006 May; 126(18):697-706. PubMed ID: 16759580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of cytochrome P450 and methods for its determination.
    Buzková H; Pechandová K; Slanar O; Perlík F
    Prague Med Rep; 2006; 107(4):383-93. PubMed ID: 17402551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.